In contrast to our previous findings with TKIs, omacetaxine did not accumulate undivided cells in vitro. Furthermore, the functionality of surviving stem cells following omacetaxine exposure was significantly reduced in a dose-dependant manner, as determined by colony forming cell and the more stringent long-term culture initiating cell colony assays. This stem cell-directed activity was not limited to CML stem cells as both normal and non-CML CD34(+) cells were sensitive to inhibition. Thus,

although omacetaxine is not leukaemia stem cell specific, its ability to induce apoptosis of leukaemic stem cells distinguishes it from TKIs and creates the potential for a curative strategy for persistent disease. Leukemia (2011) 25, 985-994; doi:10.1038/leu.2011.55; click here published online 5 April 2011″
“The capacity of human transposable elements S63845 (TEs) to promote cis natural antisense transcripts (cis-NATs) is revealed by the discovery of 48 718 human gene antisense transcriptional start sites (TSSs) within TE sequences. TSSs that yield cis-NATs are overrepresented among TE sequences, and TE-initiated cis-NATs are

more abundant close to the 3′ ends of genes. The TE sequences that promote antisense transcription within human genes are relatively ancient, suggesting that selection has acted to conserve their function.”
“Introduction Using balloon-expandable stents (BES) for treatment of intracranial stenoses, high inflation pressures and rigidity of the device are regarded as major drawbacks limiting feasibility and

safety of the procedure. Self-expanding stents (SES) were developed to facilitate lesion access and to allow for less this website aggressive dilatation. We analyzed data of the INTRASTENT multicentric registry to assess whether self-expanding stents significantly reduced peri-interventional complication rates.

Methods Records of intracranial stent procedures were entered consecutively into the registry. Datasets were divided into two groups according to the type of stent used. For outcome measurement, we chose three categories: TIA/minor stroke [modified Rankin score (mRS) < 2], disabling stroke, and patient death. Clinical outcome was compared between BES and SES. We analyzed types of adverse events occurring in each group in addition.

Results Of 409 atherosclerotic lesions, 254 were treated with BES and 155 with SES. Technical success rates were 97.6% and 98.7%, respectively. Adverse event rates were 4.9%, 3.7%, and 0.8% for TIA/nondisabling stroke, disabling stroke, and death in the BES group compared with 5.3%, 6.0%, and 4.0% in the SES group. The differences were not statistically significant. We observed more perforator strokes after use of BES, but thromboembolic events occurred more often in the SES treatment group.